Ghosn Mario, Tselikas Lambros, Champiat Stéphane, Deschamps Frederic, Bonnet Baptiste, Carre Émilie, Testan Marine, Danlos François-Xavier, Farhane Siham, Susini Sandrine, Suzzoni Steve, Ammari Samy, Marabelle Aurélien, De Baere Thierry
Radiologie Interventionnelle, Département d'Anesthésie Chirurgie Et Imagerie Interventionnelle (DACI), Gustave Roussy, Villejuif, 94800, France.
Centre D'Investigation Clinique BIOTHERIS, INSERM CIC1428, Villejuif, France.
Curr Oncol Rep. 2023 Aug;25(8):857-867. doi: 10.1007/s11912-023-01422-4. Epub 2023 May 2.
This review presents the rationale for intratumoral immunotherapy, technical considerations and safety. Clinical results from the latest trials are provided and discussed.
Intratumoral immunotherapy is feasible and safe in a wide range of cancer histologies and locations, including lung and liver. Studies mainly focused on multi-metastatic patients, with some positive trials such as T-VEC in melanoma, but evidence of clinical benefit is still lacking. Recent results showed improved outcomes in patients with a low tumor burden. Intratumoral immunotherapy can lower systemic toxicities and boost local and systemic immune responses. Several studies have proven the feasibility, repeatability, and safety of this approach, with some promising results in clinical trials. The clinical benefit might be improved in patients with a low tumor burden. Future clinical trials should focus on adequate timing of treatment delivery during the course of the disease, particularly in the neoadjuvant setting.
本综述阐述了瘤内免疫疗法的基本原理、技术考量及安全性。提供并讨论了最新试验的临床结果。
瘤内免疫疗法在包括肺癌和肝癌在内的多种癌症组织学类型和部位中是可行且安全的。研究主要集中于多转移患者，有一些阳性试验，如黑色素瘤中的T-VEC，但仍缺乏临床获益的证据。近期结果显示肿瘤负荷低的患者预后有所改善。瘤内免疫疗法可降低全身毒性并增强局部和全身免疫反应。多项研究已证实该方法的可行性、可重复性和安全性，在临床试验中取得了一些有前景的结果。肿瘤负荷低的患者临床获益可能会得到改善。未来的临床试验应关注在疾病过程中，特别是新辅助治疗环境下，给予治疗的适当时机。
